Publications by authors named "Judith Schilling"

Claim this Profile
P
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy-the MecMeth/NOA-24 trial.
Thomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, Dieter H Heiland, Michael C Burger, Judith Schilling

Trials· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The MID1 Protein: A Promising Therapeutic Target in Huntington's Disease.
Annika Heinz, Judith Schilling, Willeke van Roon-Mom, Sybille Krauß

Front Genet· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deregulated Splicing Is a Major Mechanism of RNA-Induced Toxicity in Huntington's Disease.
Judith Schilling, Meike Broemer, Ilian Atanassov, Yvonne Duernberger, Ina Vorberg

J Mol Biol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of the MID1 protein complex: a novel approach targeting APP protein synthesis.
Frank Matthes, Moritz M Hettich, Judith Schilling, Diana Flores-Dominguez, Nelli Blank

Cell Death Discov· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder.
Frank Matthes, Serena Massari, Anna Bochicchio, Kenji Schorpp, Judith Schilling

ACS Chem Neurosci· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MicroRNAs miR-19, miR-340, miR-374 and miR-542 regulate MID1 protein expression.
Kristoffer Unterbruner, Frank Matthes, Judith Schilling, Rohit Nalavade, Stephanie Weber

PLoS One· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulation of mRNA Translation by MID1: A Common Mechanism of Expanded CAG Repeat RNAs.
Nadine Griesche, Judith Schilling, Stephanie Weber, Marlena Rohm, Verena Pesch

Front Cell Neurosci· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Annkristin Heine, Judith Schilling, Barbara Grünwald, Achim Krüger, Heidrun Gevensleben

Cancer Immunol Immunother· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis